Research Progress on the Mechanisms of Panax notoginseng and Its Active Components Against Gastric Cancer and Gastric Precancerous Lesions.HOU Qingli, YANG Linglong, WU Lili, HUANG Guoxin, WANG Jingbin, ZHANG Yang

Corresponding author: zhang yang, yangzhang83@163.com

DOI: 10.12201/bmr.202604.00181

•  

  Abstract: Gastric precancerous lesions are critical pathological stages in the progression from normal gastric mucosa to gastric cancer, including atrophy, intestinal metaplasia, and dysplasia. Preventing and treating gastric precancerous lesions can effectively reduce the incidence of gastric cancer. Modern pharmacological research indicates that the main active components of the traditional Chinese medicine Panax notoginseng, such as saponins and flavonoids, can inhibit the progression of gastric precancerous lesions and treat gastric cancer through multiple pathways. These mechanisms include inhibiting abnormal cell proliferation, inducing apoptosis, regulating autophagy, alleviating inflammatory responses, repairing the gastric mucosal barrier, combating oxidative stress, and inhibiting angiogenesis, demonstrating characteristics of multi-target, multi-pathway, and multi-level actions. Current research on the mechanisms of Panax notoginseng against gastric cancer and gastric precancerous lesions is mostly focused at the cellular level, with significant deficiencies in animal-related experiments and specific clinical studies. Furthermore, besides notoginseng saponins, there is limited research on the mechanisms of other active substances such as polysaccharides and flavonoids against gastric cancer and gastric precancerous lesions. Meanwhile, the interactive regulatory network among various signaling pathways has not yet been elucidated, and systematic research on component-target-pathway interactions urgently needs to be conducted. This article reviews the active components and mechanisms of Panax notoginseng against gastric cancer and gastric precancerous lesions in recent years, aiming to provide relevant theoretical foundations for deepening research in this field.

  Key words: Panax notoginseng; Active components; Gastric cancer; Gastric precancerous lesions; Mechanism of action; Research progress

  Submit time: 30 April 2026

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• Li Lingbing, Chen Xi. The Research Progress of Traditional Chinese Medicine Monomers in Precancerous Lesions of Gastric Cancer. 2025. doi: 10.12201/bmr.202511.00037

  haoxiaoying. Clinical Research Progress of Gastrin in Gastric Precancerous Lesion. 2025. doi: 10.12201/bmr.202502.00030

  Jiyunxi. Research progress on the role of protein ubiquitination in the occurrence and development of gastric cancer. 2026. doi: 10.12201/bmr.202601.00012

  YaQin Hao, YunFeng Hu, Jing Hao, Xin Zhao. Research of circular RNA and autophagy in gastric cancer. 2023. doi: 10.12201/bmr.202304.00001

  Xu Lu-zhou. Exploring the Pathogenesis and Treatment Strategies of Gastric Inflammation-Cancer Transformation Based on the Theory of Where There is Lingering Masses, There Must Be Latent Yang. 2025. doi: 10.12201/bmr.202511.00044

  Wang Yaoqiang, Wang Haohao, Luo Changjiang. The role of HMGB1 in the progression and therapy of Gastric Cancer. 2024. doi: 10.12201/bmr.202412.00009

  YANG Jiaqi, CUI Yan. Advance in research on the prevention and treatment of gastric cancer by Traditional Chinese Medicine through modulation of programmed cell death. 2025. doi: 10.12201/bmr.202512.00063

  Gao Mengya, Zhang Qian. Research Progress on the Intervention of Sepsis Inflammatory Response Pathways by Active Components of Traditional Chinese Medicine. 2026. doi: 10.12201/bmr.202602.00025

  沈思齐, Wu Luyao, Fang Haoxiang, Shao Yanfei. Mechanism and research progress of flavonoids in prevention and treatment of nephrotic syndrome. 2025. doi: 10.12201/bmr.202511.00086

  Chen Zhifang. Research Progress on the Diagnostic and Triage Roles of PAX1 Methylation in Cervical Cancer. 2024. doi: 10.12201/bmr.202412.00067

• ID	Submit time	Number	Download
  1	2026-03-23	10.12201/bmr.202604.00181V1	Download

• Public  Anonymous  To author only Submit Comments